Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression

被引：0
|
作者：
Riedel, R. [1 ]
Michels, S. [1 ]
Heydt, C. [2 ]
Nogova, L. [1 ]
Fischer, R. N. [1 ]
Abdulla, D. S. Y. [1 ]
Scheffler, M. [1 ]
Merkelbach-Bruse, S. [2 ]
Kobe, C. [3 ]
Schaefer, S. [2 ]
Buettner, R. [2 ]
Wolf, J. [1 ]
机构：
[1] Uniklin Koln, Klin Innere Med 1, Cologne, Germany
[2] Uniklin Koln, Inst Pathol, Cologne, Germany
[3] Uniklin Koln, Klin Nukl Med, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P910
引用
收藏
页码：295 / 296
页数：2
相关论文
共 50 条
  • [21] Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement
    Schwab, Richard
    Petak, Istvan
    Kollar, Mihaly
    Pinter, Ferenc
    Varkondi, Edit
    Kohanka, Andrea
    Barti-Juhasz, Helga
    Schoenleber, Julia
    Brauswetter, Diana
    Kopper, Laszlo
    Urban, Laszlo
    LUNG CANCER, 2014, 83 (01) : 109 - 111
  • [22] A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment
    Rui Jiang
    Dongguang Wei
    Yuan Tan
    Qianqian Duan
    Investigational New Drugs, 2022, 40 : 870 - 873
  • [23] A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
    Yan Chen
    Bo Jiang
    Yuange He
    Chu Zhang
    Wenjie Zhou
    Cheng Fang
    Dejian Gu
    Minxia Zhang
    Mei Ji
    Juntao Shi
    Xin Yang
    BMC Medical Genomics, 15
  • [24] A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
    Chen, Yan
    Jiang, Bo
    He, Yuange
    Zhang, Chu
    Zhou, Wenjie
    Fang, Cheng
    Gu, Dejian
    Zhang, Minxia
    Ji, Mei
    Shi, Juntao
    Yang, Xin
    BMC MEDICAL GENOMICS, 2022, 15 (01)
  • [25] Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
    Wang, Xiaomeng
    Cao, Jie
    Du, Weijiao
    Zhang, Weihong
    Cao, Shui
    CLINICAL CASE REPORTS, 2021, 9 (07):
  • [26] Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma
    Vaz, Victor R.
    Gandhi, Malini M.
    Ricciuti, Biagio
    Alessi, Joao V.
    Elkrief, Arielle
    Ladanyi, Marc
    Vanderbilt, Chad
    Pecci, Federica
    Aldea, Mihaela
    Barrichello, Adriana
    Saini, Arushi
    Sholl, Lynette
    Sands, Jacob M.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [27] KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
    Cho, Jang Ho
    Ku, Bo Mi
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : E29 - E31
  • [28] Dramatic Response to. Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification
    Gainor, Justin F.
    Niederst, Matthew J.
    Lennerz, Jochen K.
    Dagogo-Jack, Ibiayi
    Stevens, Sara
    Shaw, Alice T.
    Sequist, Lecia V.
    Engelman, Jeffrey A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E83 - E85
  • [29] A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer
    Yang, Yang
    Zhang, Yanxiang
    Zhao, Dandan
    Li, Xiaoli
    Ma, Tonghui
    CLINICAL LUNG CANCER, 2023, 24 (01) : E50 - E54
  • [30] A lung adenocarcinoma patient harboring MET c. 3028+2 T >A variant sensitive to crizotinib treatment
    Jiang, Rui
    Wei, Dongguang
    Tan, Yuan
    Duan, Qianqian
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 870 - 873
12345